Huang Wenjie, Huang Yaohuan, Gu Jianyou, Zhang Junfeng, Yang Jiali, Liu Songsong, Xie Chuanming, Fan Yingfang, Wang Huaizhi
Department of First Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University Guangzhou 510280, Guangdong, China.
Institute of Hepatopancreatobiliary Surgery, Southwest Hospital, Army Medical University Chongqing 400038, China.
Am J Transl Res. 2019 May 15;11(5):2983-2994. eCollection 2019.
Pancreatic ductal adenocarcinoma (PDAC) is a genetic disease and a leading cause of cancer-related mortality. However, the molecular mechanism underlying PDAC progression remains unclear. In this study, we first confirmed that ECM1 is significantly upregulated in PDAC tissues and that its high levels of expression are closely associated with an advanced histologic grade and a poor prognosis using The Cancer Genome Atlas (TCGA) dataset and the Gene Expression Omnibus (GEO) database. We then found that miR-23a-5p binds directly to the ECM1 3'-untranslated region (3'-UTR), thereby inhibiting ECM1 expression. Functional studies revealed that the induced expression of ECM1 promoted oncogenic abilities and reversed the suppressive effects induced by miR-23a-5p. Collectively, our findings indicate that ECM1 is a proto-oncogene and show that targeting the miR-23a-5p/ECM1 axis may represent a promising therapeutic strategy for PDAC.
胰腺导管腺癌(PDAC)是一种遗传性疾病,也是癌症相关死亡的主要原因。然而,PDAC进展的分子机制仍不清楚。在本研究中,我们首先使用癌症基因组图谱(TCGA)数据集和基因表达综合数据库(GEO)证实,ECM1在PDAC组织中显著上调,其高表达水平与高级别组织学分级和不良预后密切相关。然后我们发现miR-23a-5p直接与ECM1的3'-非翻译区(3'-UTR)结合,从而抑制ECM1的表达。功能研究表明,ECM1的诱导表达促进了致癌能力,并逆转了miR-23a-5p诱导的抑制作用。总的来说,我们的研究结果表明ECM1是一种原癌基因,并表明靶向miR-23a-5p/ECM1轴可能是一种有前景的PDAC治疗策略。